Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SUCROSE PERMEABILITY AS MARKER OF GASTRIC DAMAGE IS 96% EFFECTIVE

This article was originally published in The Gray Sheet

Executive Summary

SUCROSE PERMEABILITY AS MARKER OF GASTRIC DAMAGE IS 96% EFFECTIVE "in predicting an abnormal endoscopy," according to a study by Lloyd Sutherland, MD, et al., GI Research Group, University of Calgary, Alberta, Canada, published in the April 23 issue of The Lancet. Concluding that measurement of sucrose permeability "provides a new way to effectively screen large populations at risk of gastric damage," the study found that while specificity for abnormal endoscopy was 96%, "sensitivity of the [sucrose permeability] test for gastric ulceration was 84%."

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel